Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB009C in Advanced Solid Tumors
NCT07326488Phase 2Recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Mar 2026
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of MHB009C in solid tumor, sponsored by Minghui Pharmaceutical, Inc.. Started Mar 2026; status: recruiting.
02
Drugs
MHB009C
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07326488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07326488.